Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

vertex pharmaceuticals australia pty ltd - ivacaftor, quantity: 125 mg; lumacaftor, quantity: 100 mg - tablet, film coated - excipient ingredients: hypromellose acetate succinate; sodium lauryl sulfate; microcrystalline cellulose; povidone; magnesium stearate; croscarmellose sodium; titanium dioxide; purified water; purified talc; brilliant blue fcf aluminium lake; polyvinyl alcohol; macrogol 3350; cochineal; indigo carmine aluminium lake; propylene glycol; butan-1-ol; isopropyl alcohol; strong ammonia solution; iron oxide black; ethanol; shellac; sulfuric acid - orkambi is indicated for the treatment of cystic fibrosis (cf) in patients aged 1 year and older who are homozygous for the f508del mutation in the cftr gene.

Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

vertex pharmaceuticals australia pty ltd - lumacaftor, quantity: 150 mg; ivacaftor, quantity: 188 mg - granules - excipient ingredients: croscarmellose sodium; microcrystalline cellulose; povidone; sodium lauryl sulfate; hypromellose acetate succinate - orkambi is indicated for the treatment of cystic fibrosis (cf) in patients aged 1 year and older who are homozygous for the f508del mutation in the cftr gene.

Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

vertex pharmaceuticals australia pty ltd - lumacaftor, quantity: 100 mg; ivacaftor, quantity: 125 mg - granules - excipient ingredients: croscarmellose sodium; microcrystalline cellulose; povidone; sodium lauryl sulfate; hypromellose acetate succinate - orkambi is indicated for the treatment of cystic fibrosis (cf) in patients aged 1 year and older who are homozygous for the f508del mutation in the cftr gene.

Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

vertex pharmaceuticals australia pty ltd - lumacaftor, quantity: 75 mg; ivacaftor, quantity: 94 mg - granules - excipient ingredients: croscarmellose sodium; hypromellose acetate succinate; microcrystalline cellulose; povidone; sodium lauryl sulfate - orkambi is indicated for the treatment of cystic fibrosis (cf) in patients aged 1 year and older who are homozygous for the f508del mutation in the cftr gene.

Austrálie - angličtina - APVMA (Australian Pesticides and Veterinary Medicines Authority)

4 farmers australia pty ltd - triclopyr present as the butoxyethyl ester - emulsifiable concentrate - triclopyr present as the butoxyethyl ester pyridine-pyridinoxy active 600.0 g/l - herbicide - commercial area - general | fallow crop land weed control | fire trail | firebreak weed control | forest | industrial land or ar - acacia genus | african boxthorn | angophora | australian or native blackthorn | banksia | bitter bark or quinine tree | black or brisbane black wattle | blackberry | brigalow | broadleaf hopbush | brooms | brown salwood or hickory wattle | budda or false sandalwood | camel or afghan melon | camphor laurel - seedling | capeweed | castor oil bush | chilean cestrum | chinee apple | common prickly pear | dawson gum | english broom | english ivy | eucalyptus - seedling and sucker | eucalyptus species - see label | fennel | furze or gorse | green or early black wattle | groundsel bush | groundsel bush - seedling | horehound | lantana - lantana camara | narrow leaf hop bush | needlewood | olive - olea europaea | paddy melon | paperbark | prickly acacia | privet | rubber vine | saffron thistle | silver wattle | smooth tree or drooping prickly pear | st john's wort | sweet briar or wild rose | tiger pear | tree-of-heaven | turpentine bush | yellow wood | afghan melon | bitter melon | black wattle | blackberry with st

Austrálie - angličtina - APVMA (Australian Pesticides and Veterinary Medicines Authority)

coromandel australia pty ltd - triclopyr present as the butoxyethyl ester - emulsifiable concentrate - triclopyr present as the butoxyethyl ester pyridine-pyridinoxy active 600.0 g/l - herbicide - agricultural non-crop areas | commercial/industrial land | fallow land | fenceline weed control | fire trail | firebreak weed co - acacia genus | african boxthorn | angophora - regrowth | australian or native blackthorn | banksia - regrowth | bitter bark or quinine tree | blackberry | blackberry in assoc with other weed (see | brigalow | broadleaf hopbush | brooms | brown salwood or hickory wattle | budda or false sandalwood | camel or afghan melon | camphor laurel | capeweed | castor oil bush | chilean cestrum | chinee apple | common prickly pear | dawson gum | english broom | english ivy | eucalyptus | eucalyptus - see label for exceptions | eucalyptus - seedling and sucker | fennel | furze or gorse | green or early black wattle | groundsel bush | horehound | lantana - lantana camara | narrow leaf hop bush | needlewood | olive - olea europaea | paddy melon | paperbark | prickly acacia | privet | rubber vine | saffron thistle | silver wattle | smooth tree or drooping prickly pear | sweet briar or wild rose | tiger pear | tree-of-heaven | turpentine bush | yellow wood | afghan melon | bitter melon | black wattle | blackberry with dock |

Austrálie - angličtina - APVMA (Australian Pesticides and Veterinary Medicines Authority)

pharmachem australia pty ltd - lanolin; iodine; pine oil; turpentine oil - topical cream, ointment, paste, gel, lotion - lanolin extract-animal active 22.5 g/l; iodine mineral-iodine active 2.0 g/l; pine oil oil-plant extract active 134.0 g/l; turpentine oil oil-plant extract active 333.0 g/l - dermatological preps. - horse | colt | donkey | endurance horse | filly | foal | gelding | high performance horses | horses at stud | mare | pacer | pol - keratolytic or cleaning agent | biotin deficiency | brittle hoof | cleansing agents | coat appearance | conditioning | conjunctivitis | cracked hoof | dry skin | flaking | galls | grooming aids | hoof conditioning | hoof moisturising | hopple chafes | itching | laminitis | moisturising | pliability | psoriasis | scratches | skin cleanser | wart removal

Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

gilead sciences pty ltd - tenofovir alafenamide fumarate, quantity: 11.2 mg; emtricitabine, quantity: 200 mg; elvitegravir, quantity: 150 mg; cobicistat, quantity: 150 mg - tablet, film coated - excipient ingredients: croscarmellose sodium; hyprolose; lactose monohydrate; magnesium stearate; sodium lauryl sulfate; microcrystalline cellulose; silicon dioxide; titanium dioxide; purified talc; iron oxide yellow; polyvinyl alcohol; macrogol 3350; indigo carmine aluminium lake - genvoya is indicated as a single tablet regimen for the treatment of hiv-1 infection in adults and paediatric patients weighing at least 25 kg who are either treatment?na?ve; or virologically suppressed (hiv-1 rna <50 copies/ml) on a stable antiretroviral regimen at start of therapy in order to replace their current antiretroviral treatment regimen (see 5.1 pharmacodynamic properties, clinical trials). patients must not have a history of treatment failure or known mutations associated with resistance to the antiretroviral components of genvoya. genvoya is a fixed dose combination of one integrase inhibitor, one pharmacokinetic enhancer and two nucleos(t)ide hiv-1 reverse transcriptase inhibitors.

Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - methylprednisolone, quantity: 4 mg - tablet - excipient ingredients: gelatin; maize starch; magnesium stearate; purified talc; lactose monohydrate - yonsa mpred is indicated for the treatment of patients with: newly diagnosed high-risk metastatic hormone sensitive prostate cancer (mhspc) in combination with androgen deprivation therapy (adt), or; patients with metastatic advanced prostate cancer (castration resistant prostate cancer, mcrpc) who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy (adt) or; patients with mcrpc who have received prior chemotherapy containing a taxane.

Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - abiraterone acetate, quantity: 250 mg - tablet - excipient ingredients: colloidal anhydrous silica; magnesium stearate; sodium lauryl sulfate; microcrystalline cellulose; croscarmellose sodium; lactose monohydrate; povidone - zytiga is indicated in combination with prednisone or prednisolone for the treatment of: ? newly diagnosed high-risk metastatic hormone sensitive prostate cancer (mhspc) in combination with androgen deprivation therapy (adt), or ? patients with metastatic advanced prostate cancer (castration resistant prostate cancer, mcrpc) who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy (adt) or ? patients with mcrpc who have received prior chemotherapy containing a taxane.